[CAS NO. 52665-69-7] Calcimycin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [52665-69-7]

Catalog

HY-N6687

Brand

MCE

CAS

52665-69-7

DESCRIPTION [52665-69-7]

Overview

MDL	-
Molecular Weight	523.62
Molecular Formula	C29H37N3O6
SMILES	O=C(C1=C2N=C(C[C@H]3O[C@]4(O[C@H]([C@H](C)C(C5=CC=CN5)=O)[C@H](C)C[C@H]4C)CC[C@H]3C)OC2=CC=C1NC)O

For research use only. We do not sell to patients.

7 Publications Citing Use of MCE

Summary

Calcimycin (A-23187) is an antibiotic and a unique divalent cation ionophore (like calcium and magnesium). Calcimycin induces Ca ²⁺ -dependent cell death by increasing intracellular calcium concentration. Calcimycin inhibits the growth of Gram-positive bacteria and some fungi. Calcimycin also inhibits the activity of ATPase and uncouples oxidative phosphorylation (OXPHOS) of mammalian cells. Calcimycin induces apoptosis ^[1] ^[2] ^[3] ^[4] .

In Vitro

Calcimycin (A-23187) mediates mycobacterial killing by inducing intracellular calcium-regulated autophagy in a P2RX7 dependent manner ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Calcimycin (A-23187) (2.5 or 7.5 nM; intrapleurally) induces protein leakage ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (ICR, 25-30 g) ^[5]
Dosage:	2.5 or 7.5 nM
Administration:	Intrapleurally
Result:	Two hours after 2.5 nM, or three hours after 7.5 nM, challenge the protein levels in the pleural cavity were equivalent to about a half of their corresponding peak values.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02992665	Assiut University	In Vitro Fertilization\|Male Factor Infertility	December 2016	Phase 2\|Phase 3
NCT04744753	MOHAMED BEHERY\|Al-Azhar University	Infertility Primary	July 15, 2017	Phase 4

Appearance

Solid

Source

Streptomyces chartreusensis

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL ( 63.65 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9098 mL	9.5489 mL	19.0978 mL
5 mM	0.3820 mL	1.9098 mL	3.8196 mL
10 mM	0.1910 mL	0.9549 mL	1.9098 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-[[(2R,3R,6S,8S,9R,11R)-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-

4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-[[3,9,11-trimethyl-8-[1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-, [6S-[6α(2S*,3S*),8β(R*),9β,11α]]-

1,7-Dioxaspiro[5.5]undecane, 4-benzoxazolecarboxylic acid deriv.

5-(Methylamino)-2-[[(2R,3R,6S,8S,9R,11R)-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-4-benzoxazolecarboxylic acid

Antibiotic A 23187

A 23187

Calcimycin

[6S-[6α(2S*,3S*),8β(R*),9β,11α]]-5-(Methylamino)-2-[[3,9,11-trimethyl-8-[1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5,5]undec-2-yl]methyl]-4-benzoxazolecarboxylic acid

Ionophore A 23187

Calimycin

Calcium ionophore A 23187

Calcium ionophore III